{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:25:59Z","timestamp":1793467559231,"version":"4.5.0"},"reference-count":53,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,22]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Dysregulated JAK\/STAT signaling underlies the pathogenesis of myelofibrosis, a myeloproliferative neoplasm characterized by cytopenias, splenomegaly, and constitutional symptoms. JAK inhibitors, such as fedratinib, are the primary therapeutic option for patients with high-risk or symptomatic myelofibrosis. Fedratinib has characteristics that distinguish it from other commercially available JAK inhibitors, such as its preferential inhibition of JAK2 and its inhibitory effects on kinases such as Fms-like tyrosine kinase 3 and BRD4. Fedratinib is most often used in the second-line setting after intolerance or resistance to other JAK inhibitors, but there is substantial evidence that it is an effective first-line option in the appropriate patient population. Prevention and early treatment of fedratinib-related gastrointestinal toxicity is key to maintaining adequate drug exposure, and clinicians must remain vigilant for Wernicke encephalopathy during treatment. Fedratinib\u2019s JAK2 selectivity and kinome profile make it an appealing agent for alternative indications, such as myelodysplastic\/myeloproliferative neoplasms and maintenance after bone marrow transplantation, which are under active investigation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015365","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T20:09:21Z","timestamp":1739563761000},"page":"1907-1915","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Fedratinib in 2025 and beyond: indications and future applications"],"prefix":"10.1182","volume":"9","author":[{"given":"Alexander","family":"Coltoff","sequence":"first","affiliation":[{"name":"1Hollings Cancer Center, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[{"name":"2The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"issue":"17","key":"2025042209114511700_bib1","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A\u00a0gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"2025042209114511700_bib2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2025042209114511700_bib3","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL 515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2025042209114511700_bib4","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1080\/10428194.2021.2010068","article-title":"Novel therapeutics and targets in myelofibrosis","volume":"63","author":"Waksal","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2025042209114511700_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","article-title":"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera","volume":"13","author":"Wernig","year":"2008","journal-title":"Cancer Cell"},{"issue":"6","key":"2025042209114511700_bib6","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1158\/1535-7163.MCT-16-0568-T","article-title":"Potent dual BET bromodomain-kinase inhibitors as value-added multitargeted chemical probes and cancer therapeutics","volume":"16","author":"Ember","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2025042209114511700_bib7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nchembio.1471","article-title":"Dual kinase-bromodomain inhibitors for rationally designed polypharmacology","volume":"10","author":"Ciceri","year":"2014","journal-title":"Nat Chem Biol"},{"issue":"7","key":"2025042209114511700_bib8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","article-title":"Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis","volume":"29","author":"Pardanani","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2025042209114511700_bib9","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: international working group-myeloproliferative neoplasms research and treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2025042209114511700_bib10","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1038\/bcj.2015.63","article-title":"A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis","volume":"5","author":"Pardanani","year":"2015","journal-title":"Blood Cancer J"},{"issue":"8","key":"2025042209114511700_bib11","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/bloodadvances.2019000954","article-title":"Fedratinib in myelofibrosis","volume":"4","author":"Mullally","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2025042209114511700_bib12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11604-020-00989-3","article-title":"Comprehensive review of Wernicke encephalopathy: pathophysiology, clinical symptoms and imaging findings","volume":"38","author":"Ota","year":"2020","journal-title":"Jpn J Radiol"},{"issue":"1","key":"2025042209114511700_bib13","first-page":"4197","article-title":"Case series of potential Wernicke\u2019s encephalopathy in patients treated with fedratinib","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2025042209114511700_bib14","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1124\/dmd.114.058883","article-title":"The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke\u2019s encephalopathy","volume":"42","author":"Zhang","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"2025042209114511700_bib15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/jcph.218","article-title":"A\u00a0randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK 2 inhibitor fedratinib (SAR 302503) in healthy volunteers","volume":"54","author":"Zhang","year":"2014","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"1","key":"2025042209114511700_bib16","first-page":"4993","article-title":"Fedratinib does not inhibit thiamine uptake or induce experimental Wernicke\u2019s encephalopathy in nonclinical studies","volume":"130","author":"Hood","year":"2017","journal-title":"Blood"},{"key":"2025042209114511700_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neulet.2017.01.041","article-title":"Treatment of rats with the JAK-2 inhibitor fedratinib does not lead to experimental Wernicke\u2019s encephalopathy","volume":"642","author":"Hazell","year":"2017","journal-title":"Neurosci Lett"},{"issue":"15","key":"2025042209114511700_bib18","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s40265-019-01205-x","article-title":"Fedratinib: first approval","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"issue":"7","key":"2025042209114511700_bib19","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"issue":"6","key":"2025042209114511700_bib20","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.25777","article-title":"Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure","volume":"95","author":"Harrison","year":"2020","journal-title":"Am J Hematol"},{"issue":"9","key":"2025042209114511700_bib21","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1080\/10428194.2024.2346733","article-title":"Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial","volume":"65","author":"Gupta","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2025042209114511700_bib22","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1016\/S2352-3026(24)00212-6","article-title":"Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"11","author":"Harrison","year":"2024","journal-title":"Lancet Haematol"},{"issue":"2","key":"2025042209114511700_bib23","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.clml.2023.09.008","article-title":"Real-world use of fedratinib for myelofibrosis following prior ruxolitinib failure: patient characteristics, treatment patterns, and clinical outcomes","volume":"24","author":"Mascarenhas","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2025042209114511700_bib24","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1111\/bjh.18284","article-title":"Limited activity of fedratinib in myelofibrosis patients relapsed\/refractory to ruxolitinib 20\u00a0mg twice daily or higher: a real-world experience","volume":"198","author":"Gangat","year":"2022","journal-title":"Br J Haematol"},{"issue":"17","key":"2025042209114511700_bib25","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2217\/fon-2022-1256","article-title":"Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis","volume":"20","author":"Passamonti","year":"2024","journal-title":"Future Oncol"},{"issue":"5","key":"2025042209114511700_bib26","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"issue":"2","key":"2025042209114511700_bib27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjh.17727","article-title":"Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis","volume":"195","author":"Pardanani","year":"2021","journal-title":"Br J Haematol"},{"issue":"9","key":"2025042209114511700_bib28","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2025042209114511700_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41408-021-00526-z","article-title":"Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis","volume":"11","author":"Sureau","year":"2021","journal-title":"Blood Cancer J"},{"issue":"7","key":"2025042209114511700_bib31","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1016\/j.clml.2022.01.016","article-title":"Thrombocytopenia in patients with myelofibrosis: pathogenesis, prevalence, prognostic impact, and treatment","volume":"22","author":"Sastow","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"2025042209114511700_bib32","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/ejh.13005","article-title":"Significance of thrombocytopenia in patients with primary and postessential thrombocythemia\/polycythemia vera myelofibrosis","volume":"100","author":"Masarova","year":"2018","journal-title":"Eur J Haematol"},{"issue":"4","key":"2025042209114511700_bib33","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.3324\/haematol.2013.101733","article-title":"The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis","volume":"99","author":"Hernandez-Boluda","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"2025042209114511700_bib34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.leukres.2017.10.002","article-title":"Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs","volume":"63","author":"Scotch","year":"2017","journal-title":"Leuk Res"},{"issue":"2","key":"2025042209114511700_bib35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/bjh.18207","article-title":"Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts","volume":"198","author":"Harrison","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"2025042209114511700_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the Mayo Clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2025042209114511700_bib37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","article-title":"Momelotinib: an emerging treatment for myelofibrosis patients with anemia","volume":"15","author":"Chifotides","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"10","key":"2025042209114511700_bib38","doi-asserted-by":"crossref","first-page":"e778","DOI":"10.1097\/HS9.0000000000000778","article-title":"Treating anemic patients with myelofibrosis in the new Janus kinase inhibitor era: Current evidence and real-world implications","volume":"6","author":"Gerds","year":"2022","journal-title":"HemaSphere"},{"issue":"17","key":"2025042209114511700_bib39","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1182\/bloodadvances.2024012939","article-title":"Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis","volume":"8","author":"Gerds","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2025042209114511700_bib40","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000521889","article-title":"Transfusion independence achieved with combination fedratinib and luspatercept in an elderly man with heavily pretreated Intermediate-2 risk primary myelofibrosis","volume":"15","author":"Yun","year":"2022","journal-title":"Case Rep Oncol"},{"issue":"1","key":"2025042209114511700_bib41","doi-asserted-by":"crossref","first-page":"S390","DOI":"10.1016\/S2152-2650(23)01234-X","article-title":"MPN-346 INDEPENDENCE: enrolling phase III trial to study the efficacy and safety of luspatercept versus placebo in patients with myelofibrosis on JAK2 inhibitor (JAK2i) therapy requiring red blood cell transfusions (RBCTs)","volume":"23","author":"Kiladjian","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2025042209114511700_bib42","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00280-020-04084-2","article-title":"Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment","volume":"85","author":"Ogasawara","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"2025042209114511700_bib43","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41375-021-01276-4","article-title":"Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT","volume":"35","author":"Kr\u00f6ger","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"2025042209114511700_bib44","doi-asserted-by":"crossref","first-page":"S372","DOI":"10.1016\/j.jtct.2023.12.521","article-title":"The use of fedratinib (FEDR) for myelofibrosis (MF) as a potential bridge to hematopoietic stem cell transplantation (HSCT) after ruxolitinib (RUX) failure: real-world assessment of treatment characteristics and spleen, symptoms, and hematologic response","volume":"30","author":"Mascarenhas","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"2025042209114511700_bib45","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1182\/blood-2021-151978","article-title":"Triple-negative myelofibrosis: disease features, response to treatment and outcomes","volume":"138","author":"Aguirre","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2025042209114511700_bib46","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2023-174917","article-title":"Comparison of the enzymatic and cellular profiles of clinical JAK2 inhibitors for the treatment of myelofibrosis","volume":"142","author":"Celik","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2025042209114511700_bib47","doi-asserted-by":"crossref","first-page":"839","DOI":"10.4155\/fmc-2017-0084","article-title":"What structural modifications can be used for BRD4 inhibitors for their use in leukemia therapy?","volume":"9","author":"Yao","year":"2017","journal-title":"Future Med Chem"},{"issue":"32","key":"2025042209114511700_bib48","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1200\/JCO.22.01972","article-title":"MANIFEST: pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naive myelofibrosis","volume":"41","author":"Mascarenhas","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2025042209114511700_bib49","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1182\/blood-2023-182879","article-title":"A phase 2 study of fedratinib in patients with MDS\/MPN and chronic neutrophilic leukemia","volume":"142","author":"Kuykendall","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2025042209114511700_bib50","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1007\/s00277-021-04618-5","article-title":"Phase II study of single-agent nivolumab in patients with myelofibrosis","volume":"100","author":"Abou Dalle","year":"2021","journal-title":"Ann Hematol"},{"issue":"23","key":"2025042209114511700_bib51","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1182\/bloodadvances.2021005491","article-title":"PD-1 inhibition in advanced myeloproliferative neoplasms","volume":"5","author":"Hobbs","year":"2021","journal-title":"Blood Adv"},{"issue":"429","key":"2025042209114511700_bib52","doi-asserted-by":"crossref","first-page":"eaam7729","DOI":"10.1126\/scitranslmed.aam7729","article-title":"Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms","volume":"10","author":"Prestipino","year":"2018","journal-title":"Sci Transl Med"},{"issue":"8","key":"2025042209114511700_bib53","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1007\/s00277-024-05867-w","article-title":"FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN)","volume":"103","author":"Isfort","year":"2024","journal-title":"Ann Hematol"},{"issue":"1","key":"2025042209114511700_bib54","doi-asserted-by":"crossref","first-page":"e2300234","DOI":"10.1200\/PO.23.00234","article-title":"Discontinuation syndrome with JAK2 selective agents: case presentation and mechanistic insights","volume":"8","author":"Handa","year":"2024","journal-title":"JCO Precision Oncology"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/8\/1907\/2368426\/blooda_adv-2024-015365-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/8\/1907\/2368426\/blooda_adv-2024-015365-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T13:12:01Z","timestamp":1745327521000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/8\/1907\/535590\/Fedratinib-in-2025-and-beyond-indications-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,4,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015365","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}